FDA Advisory Committees Under Scrutiny: The Case for Reform After Capricor's Deramiocel Review
Key Insights
FDA Advisory Committee meetings remain pivotal regulatory catalysts that can trigger sharp biotech stock swings, as illustrated by Moderna's 9.6% intraday gain following a unanimous positive vote for its influenza vaccine mRNA-1010.
The FDA is not bound by AdCom votes; it has approved drugs despite negative panel recommendations (e.g., Zynquista in 2024) and rejected drugs after positive votes (e.g., Teplizumab in 2021).
The recent Capricor Therapeutics AdCom for deramiocel in Duchenne muscular dystrophy (search) highlighted the need for temporary voting members with specialized disease expertise on advisory panels.
The FDA's advisory committee process—one of the agency's most transparent and closely watched institutional strengths—is facing renewed calls for reform following the recent Capricor Therapeutics review for deramiocel, a proposed treatment for cardiomyopathy (search) associated with Duchenne muscular dystrophy (search). The meeting, which convened to evaluate exceptionally difficult scientific questions involving small patient populations, imperfect endpoints, and natural-history controls, has become a flashpoint in a broader debate about who should sit around the table when the FDA confronts its toughest regulatory decisions.
The stakes of these proceedings extend well beyond any single drug. Advisory Committee meetings, or AdComs, are among the most visible regulatory catalysts in biotech, often triggering sharp stock price movements before, during, and after the vote. In one recent example, Moderna's stock climbed approximately 9.6%—from a close of $61.80 to an intraday high of $67.74—following a unanimous AdCom vote in favor of its investigational influenza vaccine mRNA-1010 in June 2026.
How AdComs Shape Regulatory Outcomes
An FDA Advisory Committee is a panel of outside experts—physicians, statisticians, patient representatives, and subject-matter specialists—convened to evaluate clinical trial data, safety findings, and risk-benefit considerations for a drug or device application. While the FDA makes the final decision, the AdCom vote provides a transparent signal of expert opinion and often shapes investor expectations.
Crucially, the FDA is not bound by these votes. The agency has, on multiple occasions, diverged from panel recommendations in both directions. In October 2024, an FDA Advisory Committee voted against Lexicon Pharmaceuticals' NDA for Zynquista (sotagliflozin) in type 1 diabetes (search) and chronic kidney disease (search), citing safety concerns and trial limitations. Despite the negative panel vote, the FDA later granted approval, recognizing the drug's potential benefit for patients with limited treatment options.
Conversely, in May 2021, an AdCom voted in favor of Provention Bio (search)'s teplizumab to delay onset of clinical type 1 diabetes (search). Yet in July 2021, the FDA issued a Complete Response Letter requesting additional data. The therapy ultimately received approval in November 2022 under the brand name Tzield—underscoring that even a positive AdCom vote does not guarantee immediate approval.
The Capricor Case and the Expertise Gap
The Capricor advisory committee, scheduled for July 29, 2026, ahead of an August 22 PDUFA date, brought into focus what some observers see as a structural weakness in the current system. Deramiocel raised complex scientific questions that the standing committee—while bringing impressive expertise in statistics, epidemiology, cardiology, neurology, and radiology—may not have been optimally equipped to address.
"The committee concluded that the evidence did not constitute substantial evidence of effectiveness, but the vote itself revealed relatively little about the committee's reasoning," noted one analysis of the proceedings. "Did members question the biological effect, the clinical endpoints, the statistical methodology or simply conclude that the legal standard had not been satisfied? Different members may well have reached the same conclusion for entirely different reasons."
This opacity has fueled arguments that FDA should restructure how advisory committees evaluate specialized therapies. The agency already possesses the authority to appoint temporary voting members whose expertise matches the application under review—an authority critics say should be used far more aggressively.
"When FDA reviews a Duchenne therapy, it should recruit physicians who care for Duchenne patients every day, pediatric cardiologists who understand the disease's unique cardiac progression, investigators who have designed Duchenne clinical trials and scientists who have developed the field's natural-history databases," advocates argue. "The objective should not be to assemble the most available committee. It should be to assemble the right committee."
Beyond a Single Yes-or-No Vote
Reform proponents also contend that the voting framework itself needs modernization. Rather than a single binary question on approvability, FDA should ask advisory committees to vote on specific scientific dimensions: whether endpoints are clinically meaningful, whether imaging measures are reliable, whether statistical analyses are persuasive, and which patient subgroups appear most likely to benefit. Such granularity would provide FDA, physicians, patients, and investors with far more useful guidance.
The conflict-of-interest framework also warrants refinement, according to those pushing for change. While individuals with direct financial interests should not vote, FDA should not unnecessarily exclude leading specialists simply because they have participated in legitimate clinical research or advised companies developing therapies. In rare diseases such as Duchenne muscular dystrophy (search) and ALS (search), expertise is scarce, and treating experience as a liability often excludes precisely the people the agency most needs to hear from.
Investor Implications
For biotech investors, AdComs remain binary events that can sharply influence valuation. In the lead-up to meetings, sentiment is shaped by FDA briefing documents—typically released two days prior—and analyst commentary. On the day of the meeting, volatility characteristically spikes as panel discussions unfold and the vote is announced.
The Capricor experience underscores that the composition of the committee itself can become a material factor in how the market interprets outcomes. As one analysis concluded: "Predictable committees produce predictable advice. Exceptional committees ask better questions, identify weaknesses others miss and often change the way FDA thinks about difficult scientific problems."
The broader lesson, reform advocates argue, extends well beyond any single meeting. Standing committees should provide continuity and institutional memory. Temporary voting members should provide specialized expertise. And the hardest scientific questions deserve the best scientific minds—a standard the FDA should settle for nothing less than when building its advisory committees.